drugset / Trial / NCT00620451
Randomized, Double-Blind, Placebo-Controlled Study of Larazotide Acetate in Subjects With Active Celiac Disease
RandomizedParallel-groupDouble-blindTreatment
Summary
This study was conducted to assess the safety and efficacy of larazotide acetate versus placebo in inducing remission in subjects with active celiac disease.
Timeline
- Start
- 2008-02
- Primary completion
- 2009-07
- Completion
- 2009-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Larazotide | Peptide | 4 mg | — |
| Subject | Larazotide | Peptide | 8 mg | — |